TGFB2

Across TCGA pan-cancer cohorts, TGFB2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of TGFB2’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where TGFB2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TGFB2 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

PDAC, HNSC, and LUAD are the cancer types where TGFB2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TGFB2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	II,III,IV	+1.349	<.001	8	view →
HNSC	Male	III,IV	+0.649	<.001	8	view →
LUAD	Female	II,III,IV	−0.608	<.001	8	view →
CCRCC	All	All	+0.550	<.001	6	view →
LSCC	All	All	−0.290	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

TGFB2–PDAC

Open the PDAC breakdown →